Suppr超能文献

路易小体:旁观者还是主要杀手?

Lewy Bodies: A Spectator or Salient Killer?

作者信息

Sian-Hulsmann Jeswinder, Monoranu Camelia, Strobel S, Riederer Peter

机构信息

Center of Mental Health, Department Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, D-97080 Würzburg, Germany.

出版信息

CNS Neurol Disord Drug Targets. 2015;14(7):947-55. doi: 10.2174/1871527314666150317225659.

Abstract

Lewy bodies (LBs) are characteristic hallmarks of Parkinson's disease (PD). However, their role in the pathology of PD is not established yet. Are they primary events in the neurodegenerative process or only secondary phenomena? Are they signs of protecting neurons from toxicity or are they toxic per se? How are they are formed? Are LBs targets for therapeutic strategies? Addressing these questions may be of pivotal importance to unravel the basic mechanisms of neurodegeneration in PD. On the basis of current evidence, we intend to elucidate the possible role of LBs as triggers and/or markers of disease progression in PD. We present evidence for the morphogenesis of brain stem and cortical LBs, the role in neuronal cell death mechanisms, which seem to be correlated with the adhesion of LBs to and finally disruption of their inner neuronal membrane. Taken as such, LBs would be salient killers of nerve cells. However, they may also play a neuroprotective role in the early phases of neuronal pathology (LBs as a spectator), yet harmful to neuronal stability in later stages of LB development. Generation of LB pathology in the periphery (early subclinical Braak stage) might be due to reactive oxygen species (ROS) due to (chronic) bacteria-induced and/or otherwise intestinal inflammation, both leading to alpha-synuclein structural changes, oligomerization, seeding and propagation in a prion-like mechanism. If so, LB generation is a secondary process following ROS/inflammation pathology. Therapeutic implication based on LB pathology include drug development to inhibit protein misfolding, templating and transmission or vaccination against LBs, neuron regeneration strategies, anti-inflammatory and anti-biotic drugs as well as nutritional specialities to prevent intestine intoxications. In conclusion, evidence suggests LBs to be secondary hallmarks of PD pathology, induced by ROS/inflammation or other pathological triggers able to modify protein (alpha-synuclein) steric/chemical properties. Therapeutic strategies based on LB pathologies are devoted to reduce neuron cell death mechanisms in their time course and severity.

摘要

路易小体(LBs)是帕金森病(PD)的特征性标志。然而,它们在PD病理过程中的作用尚未明确。它们是神经退行性过程中的原发性事件,还是仅仅是继发性现象?它们是保护神经元免受毒性的标志,还是本身就具有毒性?它们是如何形成的?路易小体是否是治疗策略的靶点?解决这些问题对于阐明PD神经退行性变的基本机制可能至关重要。基于目前的证据,我们旨在阐明路易小体作为PD疾病进展的触发因素和/或标志物的可能作用。我们提供了脑干和皮质路易小体形态发生的证据,以及它们在神经元细胞死亡机制中的作用,这似乎与路易小体与神经元内膜的粘附以及最终对其的破坏有关。照此来看,路易小体将是神经细胞的主要杀手。然而,它们也可能在神经元病理的早期阶段发挥神经保护作用(路易小体作为旁观者),但在路易小体发展的后期对神经元稳定性有害。外周路易小体病理的产生(早期亚临床Braak阶段)可能是由于(慢性)细菌诱导的和/或以其他方式引起的肠道炎症导致的活性氧(ROS),两者均导致α-突触核蛋白结构改变、寡聚化、种子形成并以朊病毒样机制传播。如果是这样,路易小体的产生是ROS/炎症病理之后的继发过程。基于路易小体病理的治疗意义包括开发抑制蛋白质错误折叠、模板化和传播的药物,或针对路易小体的疫苗接种、神经元再生策略、抗炎和抗生素药物以及预防肠道中毒的营养特产。总之,有证据表明路易小体是PD病理的继发性标志,由ROS/炎症或其他能够改变蛋白质(α-突触核蛋白)空间/化学性质的病理触发因素诱导。基于路易小体病理的治疗策略致力于在时间进程和严重程度上减少神经元细胞死亡机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验